Advances in cancer research最新文献_第3页

Systemic therapy landscape of advanced prostate cancer. 晚期前列腺癌的系统治疗前景。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-27 DOI: 10.1016/bs.acr.2024.04.004

Asit K Paul, John W Melson, Samina Hirani, Selvaraj Muthusamy

引用次数: 0

Melanoma redox biology and the emergence of drug resistance. 黑色素瘤氧化还原生物学和耐药性的出现。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI: 10.1016/bs.acr.2024.06.004

Therese Featherston, Martina Paumann-Page, Mark B Hampton

引用次数: 0

Data enhancement in the age of spatial biology. 空间生物学时代的数据增强。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1016/bs.acr.2024.06.008

Linbu Liao, Patrick C N Martin, Hyobin Kim, Sanaz Panahandeh, Kyoung Jae Won

引用次数: 0

Recent advances and progress in immunotherapy of solid cancers. 实体癌免疫疗法的最新进展。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.acr.2024.05.004

Amit Kumar, Luni Emdad, Swadesh K Das, Paul B Fisher

{"title":"Recent advances and progress in immunotherapy of solid cancers.","authors":"Amit Kumar, Luni Emdad, Swadesh K Das, Paul B Fisher","doi":"10.1016/bs.acr.2024.05.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.05.004","url":null,"abstract":"Adoptive cell therapy using chimeric antigen receptor (CAR) technology has become mainstream by employing advanced engineering platforms to promote cancer immunotherapy. CAR T cells have shown remarkable efficacy in the treatment of hematological malignancies; however, the value of this therapy remains inconclusive in the context of solid tumors. Immunotherapy of solid tumors is restrained by several obstacles including the presence of an immunosuppressive tumor microenvironment (TME), limited tumor trafficking, inhibited immune cell infiltration, absence of tumor-specific antigens, and off-target toxicity and adverse events associated with these therapies. Despite recent advances in CAR T cell construction, including the integration of co-stimulatory domains and the creation of armed CAR T cells, with promising outcomes in the treatment of some solid tumors, there are still many unresolved obstacles that need to be overcome. To surmount these impediments to effective CAR T cell therapies, other immune cells, such as natural killer cells and macrophages, have been engineered to serve as appealing alternatives for successful cancer immunotherapy of solid tumors. CAR NK cells demonstrate significant clinical advantages due to their ready availability and minimal toxicity. CAR macrophage (M) cells provide considerable therapeutic potential due to their ability to penetrate the TME of solid tumors. In this review, we comprehensively examine the latest developments and prospects of engineered immune cell-based cancer immunotherapies specifically designed for treating solid tumors. In addition, we provide a concise overview of current clinical trials that are examining the safety and effectiveness of modified immune cells, such as CAR T, CAR NK, and CAR M, in their ability to specifically target solid tumors and promote improved therapeutic outcomes in patients with diverse solid cancers.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"111-190"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The glycosylation landscape of prostate cancer tissues and biofluids. 前列腺癌组织和生物流体的糖基化图谱

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-25 DOI: 10.1016/bs.acr.2024.04.005

Jordan Hartig, Lyndsay E A Young, Grace Grimsley, Anand S Mehta, Joseph E Ippolito, Robin J Leach, Peggi M Angel, Richard R Drake

{"title":"The glycosylation landscape of prostate cancer tissues and biofluids.","authors":"Jordan Hartig, Lyndsay E A Young, Grace Grimsley, Anand S Mehta, Joseph E Ippolito, Robin J Leach, Peggi M Angel, Richard R Drake","doi":"10.1016/bs.acr.2024.04.005","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.04.005","url":null,"abstract":"An overview of the role of glycosylation in prostate cancer (PCa) development and progression is presented, focusing on recent advancements in defining the N-glycome through glycomic profiling and glycoproteomic methodologies. Glycosylation is a common post-translational modification typified by oligosaccharides attached N-linked to asparagine or O-linked to serine or threonine on carrier proteins. These attached sugars have crucial roles in protein folding and cellular recognition processes, such that altered glycosylation is a hallmark of cancer pathogenesis and progression. In the past decade, advancements in N-glycan profiling workflows using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI-MSI) technology have been applied to define the spatial distribution of glycans in PCa tissues. Multiple studies applying N-glycan MALDI-MSI to pathology-defined PCa tissues have identified significant alterations in N-glycan profiles associated with PCa progression. N-glycan compositions progressively increase in number, and structural complexity due to increased fucosylation and sialylation. Additionally, significant progress has been made in defining the glycan and glycopeptide compositions of prostatic-derived glycoproteins like prostate-specific antigen in tissues and biofluids. The glycosyltransferases involved in these changes are potential drug targets for PCa, and new approaches in this area are summarized. These advancements will be discussed in the context of the further development of clinical diagnostics and therapeutics targeting glycans and glycoproteins associated with PCa progression. Integration of large scale spatial glycomic data for PCa with other spatial-omic methodologies is now feasible at the tissue and single-cell levels.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"1-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redox pathways in melanoma. 黑色素瘤的氧化还原途径

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-24 DOI: 10.1016/bs.acr.2024.06.002

Jie Zhang, Zhi-Wei Ye, Danyelle M Townsend, Kenneth D Tew

引用次数: 0

Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer. 前列腺癌治疗的进展：前列腺癌的放射性核素治疗。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1016/bs.acr.2024.07.004

Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata

{"title":"Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.","authors":"Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata","doi":"10.1016/bs.acr.2024.07.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.07.004","url":null,"abstract":"The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting 177Lu-PSMA radionuclide therapy have demonstrated the utility of 177Lu-PSMA in the treatment of mCRPC. Further research into alpha-emitting radionuclide therapy and vectors may provide alternative treatments for patients with treatment resistant mCRPC. As radionuclide therapy treatment options evolve, assessing appropriate patient selection for radionuclide therapy is important and may be facilitated by advances in imaging and blood-based biomarkers. Exploration of other approved life prolonging therapies in combination with radionuclide therapy has shown increasing interest as a potential method of combatting radionuclide therapy resistance. In this chapter, we review various types of radionuclide therapies for mCRPC, patient selection for radionuclide therapy from outcome predictions, ongoing clinical trials of radiopharmaceuticals for treatment of prostate cancer, and the resistance mechanisms and challenges to radionuclide therapy.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"311-358"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deep learning-based multimodal spatial transcriptomics analysis for cancer. 基于深度学习的癌症多模态空间转录组学分析

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-08-22 DOI: 10.1016/bs.acr.2024.08.001

Pankaj Rajdeo, Bruce Aronow, V B Surya Prasath

{"title":"Deep learning-based multimodal spatial transcriptomics analysis for cancer.","authors":"Pankaj Rajdeo, Bruce Aronow, V B Surya Prasath","doi":"10.1016/bs.acr.2024.08.001","DOIUrl":"10.1016/bs.acr.2024.08.001","url":null,"abstract":"The advent of deep learning (DL) and multimodal spatial transcriptomics (ST) has revolutionized cancer research, offering unprecedented insights into tumor biology. This book chapter explores the integration of DL with ST to advance cancer diagnostics, treatment planning, and precision medicine. DL, a subset of artificial intelligence, employs neural networks to model complex patterns in vast datasets, significantly enhancing diagnostic and treatment applications. In oncology, convolutional neural networks excel in image classification, segmentation, and tumor volume analysis, essential for identifying tumors and optimizing radiotherapy. The chapter also delves into multimodal data analysis, which integrates genomic, proteomic, imaging, and clinical data to offer a holistic understanding of cancer biology. Leveraging diverse data sources, researchers can uncover intricate details of tumor heterogeneity, microenvironment interactions, and treatment responses. Examples include integrating MRI data with genomic profiles for accurate glioma grading and combining proteomic and clinical data to uncover drug resistance mechanisms. DL's integration with multimodal data enables comprehensive and actionable insights for cancer diagnosis and treatment. The synergy between DL models and multimodal data analysis enhances diagnostic accuracy, personalized treatment planning, and prognostic modeling. Notable applications include ST, which maps gene expression patterns within tissue contexts, providing critical insights into tumor heterogeneity and potential therapeutic targets. In summary, the integration of DL and multimodal ST represents a paradigm shift towards more precise and personalized oncology. This chapter elucidates the methodologies and applications of these advanced technologies, highlighting their transformative potential in cancer research and clinical practice.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"1-38"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11431148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-cancer activity of capsaicin and its analogs in gynecological cancers. 辣椒素及其类似物在妇科癌症中的抗癌活性。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.acr.2024.05.005

Kathleen C Brown, Amanda M Sugrue, Kaitlyn B Conley, Kushal J Modi, Reagan S Light, Ashley J Cox, Christopher R Bender, Sarah L Miles, Krista L Denning, Paul T Finch, Joshua A Hess, Maria T Tirona, Monica A Valentovic, Piyali Dasgupta

{"title":"Anti-cancer activity of capsaicin and its analogs in gynecological cancers.","authors":"Kathleen C Brown, Amanda M Sugrue, Kaitlyn B Conley, Kushal J Modi, Reagan S Light, Ashley J Cox, Christopher R Bender, Sarah L Miles, Krista L Denning, Paul T Finch, Joshua A Hess, Maria T Tirona, Monica A Valentovic, Piyali Dasgupta","doi":"10.1016/bs.acr.2024.05.005","DOIUrl":"10.1016/bs.acr.2024.05.005","url":null,"abstract":"Capsaicin is the hot and pungent ingredient of chili peppers. It is a potent pain-relieving agent and is often present in over-the-counter analgesic lotions and creams. Several convergent studies reveal that capsaicin displays growth-suppressive activity in human cancers in vitro and in vivo. Apart from its growth-suppressive activity (as a single agent), capsaicin has been found to sensitize human cancer cells to the pro-apoptotic effects of chemotherapy and radiation. The first part of this book chapter discusses the anti-cancer activity of capsaicin in gynecological cancers in cell culture experiments and mouse models. Out of all gynecological cancers, the anti-cancer activity of capsaicin (and its analogs) has only been investigated in cervical cancers and ovarian cancers. The clinical development of capsaicin as a viable anti-cancer drug has remained challenging due to its poor bioavailability and aqueous solubility properties. In addition, the administration of capsaicin is associated with adverse side effects like gastrointestinal cramps, stomach pain, irritation in the gut, nausea diarrhea and vomiting. Two strategies have been investigated to overcome these drawbacks of capsaicin. The first is to encapsulate capsaicin in sustained release drug delivery systems. The second strategy is to design non-pungent capsaicin analogs which will retain the anti-tumor activity of capsaicin. The second part of this chapter provides an overview of the anti-neoplastic (and chemosensitization activity) of capsaicin analogs and capsaicin-based sustained release formulations in cervical and ovarian cancers. The design of selective non-pungent capsaicin analogs and capsaicin-based polymeric drug delivery systems may foster the hope of novel strategies for the treatment and management of gynecological cancers.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"241-281"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 序言

Advances in cancer research Pub Date : 2024-01-01 DOI: 10.1016/S0065-230X(24)00079-4

Esha Madan, Paul B Fisher, Rajan Gogna

引用次数: 0